QHP Capital L.P. (“QHP”), a Raleigh-based private equity firm which manages the NovaQuest Private Equity family of funds, today announced a single asset continuation fund (the “Catalyst SPV”) backing Catalyst Clinical Research LLC (“Catalyst” or the “Company”), a global contract research organization (“CRO”), providing full-service clinical development support for oncology-focused biotechs. QHP originally invested in Catalyst in October 2018 through NovaQuest Private Equity Fund I, L.P. (“Fund I”). As part of a buy-and-build strategy, QHP and Catalyst have made four add-on acquisitions, creating a full-service, oncology-focused CRO (Catalyst Oncology) operating alongside the legacy FSP services now marketed as Catalyst Flex.
Read the full article: QHP Capital Forms Continuation Vehicle for Catalyst Clinical Research //
Source: https://www.businesswire.com/news/home/20221101005380/en/QHP-Capital-Forms-Continuation-Vehicle-for-Catalyst-Clinical-Research